Welcome to Agile R100

Reliable kinetic binding data at your benchtop… and under your control.

THE POWER TO ACHIEVE

The easy-to-learn label-free Agile R100 assay makes it simple to get kinetic binding data earlier in the drug discovery process when you need it most. Built with highly sensitive, proprietary Field Effect Biosensing (FEB) technology, Agile R100 enables you to gain on and off rates and affinity rankings at the comfort of your benchtop, giving you complete control over the characterization of your biomolecules.

Validate your hits with a novel orthogonal approach and achieve measurements never before possible!

High sensitivity with AGILE R100

SENSITIVE

10 µL of sample

11-log dynamic range

Label-free measurements with AGILE R100

SIMPLE

Label-free reduces

design complexity

AGILE R100 is a benchtop tool

PORTABLE

Personal system

weighing 2 lbs.

AGILE R100 provides fast measurements in 2 minutes

FAST

Assay development

Sense in 2 minutes

SENSITIVE LABEL-FREE RESULTS WITH AGILE R100

Agile R100’s open-pipetting design enables on-the-fly assay modification, vastly reducing assay development time.
See how it’s used in this 1:32 video!

NEW PUBLICATION ON FEB SIGNAL-TO-NOISE RATIO COMPARED TO BLI AND ELISA

Agile R100, a Field Effect Biosensing (FEB) system, detected Zika viral antigen at a concentration 10 times lower than on a BLI system in this breakthrough study. The platform also lowered the limit of detection by 10 times versus on an ELISA for inflammatory protein IL-6.

EVENTS

Join us to learn more about the Agile R100 orthogonal approach to biophysical characterization!

Nanomedical Diagnostics 2018 Society for Laboratory Automation and Screening Conference booth

2018 Society for Laboratory Automation and Screening

We’ll be in Booth 332 at the 2018 the Society for Laboratory Automation and Screening (SLAS) conference in San Diego from Feb. 3-7 to launch Agile R200, the only high-throughput biophysical data platform compatible with automated liquid handlers.

PARTNERS

CRADA with the CDC to evaluate direct electronic detection for disease diagnostic systems.
DARPA grant awarded to develop hand-held drug therapeutic monitoring devices.
Mayo Clinic evaluating the diagnostic capabilities of field effect biosensor chips.
Stanford School of Medicine using AGILE R100 for in vitro kinetic binding data.